21 Jan 2021 12:40
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) | Barclays PLC. | |
Company dealt in | WILLIS TOWERS WATSON PLC | |
Class of relevant security to which the | ORD | |
dealings being disclosed relate (Note 2) | ||
Date of dealing | 20 January 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
Class of relevant security: | ORD | ||||
Long | Short | ||||
Number | (%) | Number | (%) | ||
(1) | Relevant securities |
|
|
|
|
2,520,645 | 1.96% | 598,821 | 0.46% | ||
|
|
|
| ||
(2) | Derivatives (other than options): |
|
|
|
|
272,825 | 0.21% | 445,393 | 0.35% | ||
|
|
|
| ||
(3) | Options and agreements to |
|
|
|
|
purchase/sell: | 6,000 | 0.00% | 6,000 | 0.00% | |
|
|
|
| ||
TOTAL: |
|
|
|
| |
2,799,470 | 2.17% | 1,050,214 | 0.81% | ||
|
|
|
|
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: | Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities |
|
| ||||
(2) Derivatives (other than options) |
|
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total |
|
| ||||
|
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale | Number of relevant securities | Price per unit |
Purchase | 1 | 209.3200 USD |
Purchase | 1 | 210.4150 USD |
Purchase | 1 | 209.2000 USD |
Purchase | 2 | 210.7550 USD |
Purchase | 2 | 210.4700 USD |
Purchase | 2 | 208.0400 USD |
Purchase | 6 | 210.6100 USD |
Purchase | 19 | 207.8636 USD |
Purchase | 45 | 207.7800 USD |
Purchase | 56 | 210.2732 USD |
Purchase | 69 | 209.7746 USD |
Purchase | 100 | 210.3700 USD |
Purchase | 200 | 208.8400 USD |
Purchase | 340 | 209.4160 USD |
Purchase | 400 | 209.7200 USD |
Purchase | 484 | 209.4766 USD |
Purchase | 728 | 209.9784 USD |
Purchase | 783 | 209.8657 USD |
Purchase | 982 | 209.6317 USD |
Purchase | 1,075 | 209.5881 USD |
Purchase | 1,285 | 209.5649 USD |
Purchase | 1,469 | 209.6580 USD |
Purchase | 1,562 | 209.4462 USD |
Purchase | 1,611 | 209.6413 USD |
Purchase | 1,976 | 209.5425 USD |
Purchase | 7,002 | 209.4200 USD |
Purchase | 7,564 | 210.2397 USD |
Purchase | 7,915 | 209.9274 USD |
Purchase | 9,208 | 210.2700 USD |
Purchase | 9,482 | 209.5144 USD |
Purchase | 10,533 | 209.5897 USD |
Purchase | 19,658 | 209.5539 USD |
Purchase | 19,839 | 209.7013 USD |
Purchase | 22,704 | 209.5922 USD |
Sale | 1 | 208.3500 USD |
Sale | 2 | 207.6400 USD |
Sale | 2 | 208.0400 USD |
Sale | 2 | 208.2400 USD |
Sale | 2 | 208.0900 USD |
Sale | 3 | 206.6500 USD |
Sale | 5 | 209.1000 USD |
Sale | 6 | 208.8066 USD |
Sale | 9 | 208.1600 USD |
Sale | 10 | 207.7400 USD |
Sale | 25 | 210.3700 USD |
Sale | 53 | 210.1760 USD |
Sale | 61 | 210.2581 USD |
Sale | 100 | 210.5600 USD |
Sale | 100 | 210.7200 USD |
Sale | 100 | 210.4100 USD |
Sale | 100 | 209.6750 USD |
Sale | 145 | 208.5110 USD |
Sale | 233 | 209.2448 USD |
Sale | 285 | 210.5270 USD |
Sale | 503 | 209.2998 USD |
Sale | 599 | 210.0147 USD |
Sale | 600 | 209.7266 USD |
Sale | 660 | 210.3004 USD |
Sale | 1,462 | 209.4305 USD |
Sale | 1,611 | 209.6413 USD |
Sale | 5,638 | 209.8466 USD |
Sale | 7,464 | 210.2585 USD |
Sale | 8,980 | 210.2700 USD |
Sale | 9,319 | 209.5224 USD |
Sale | 21,224 | 209.5596 USD |
Sale | 67,800 | 209.6135 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (Note 5) |
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 (Open Positions) attached? | YES |
Date of disclosure: | 21 Jan 2021 |
Contact name: | Large Holdings Regulatory Operations |
Telephone number: | 020 3134 7213 |
If a connected EFM, name of offeree/offeror with which connected | |
If a connected EFM, state nature of connection |
Ap23
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)
OPEN POSITIONS (Note 1)
Product name | Written or | Number of | Exercise | Type | Expiry |
purchased | relevant securities | price | date | ||
to which the option | |||||
or derivative | |||||
relates | |||||
Call Options | Purchased | 6,000 | 220.0000 | American | Jul 16, 2021 |
Put Options | Purchased | -6,000 | 200.0000 | American | Jul 16, 2021 |
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005502/en/
Copyright Business Wire 2021